Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis

Effectiveness of Certolizumab-Pegol in Rheumatoid Arthritis, Spondyloarthritis, and Psoriatic Arthritis Based on the BIOPURE Registry: Can Early Response Predict Late Outcomes?

(2019) Florenzo Iannone et al.   CLINICAL DRUG INVESTIGATION

The use of biologics for uveitis associated with spondyloarthritis

(2019) Sruthi Arepalli et al.   CURRENT OPINION IN RHEUMATOLOGY

An update on pathogenesis of psoriatic arthritis and potential therapeutic targets

(2019) Maria Sole Chimenti et al.   Expert Review of Clinical Immunology

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

(2018) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

(2018) Alice B. Gottlieb et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

(2018) A. Blauvelt et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis

(2018) Jasvinder A. Singh et al.   Arthritis & Rheumatology

Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis

(2017) Yu Woo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Psoriasis pathogenesis and the development of novel targeted immune therapies

(2017) Jason E. Hawkes et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pathogenesis of psoriasis and development of treatment

(2017) Eisaku Ogawa et al.   JOURNAL OF DERMATOLOGY

Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database

(2017) Peter Bhoi et al.   BMJ Open

Tumor necrosis factor inhibitors in psoriatic arthritis

(2017) Santhi Mantravadi et al.   Expert Review of Clinical Pharmacology

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

(2016) M. Rudwaleit et al.   ARTHRITIS CARE & RESEARCH

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

(2015) L Gossec et al.   ANNALS OF THE RHEUMATIC DISEASES

Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease

(2015) James T. Rosenbaum   CLINICAL RHEUMATOLOGY

Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis

(2015) Alessia Alunno et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics

(2015) F. Carubbi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

(2015) A. Nast et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study

(2014) A Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study

(2013) D. Gladman et al.   ARTHRITIS CARE & RESEARCH

High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires

(2012) Muhammad Haroon et al.   ANNALS OF THE RHEUMATIC DISEASES

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

(2012) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

(2010) Batya B. Davidovici et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Certolizumab Pegol

(2010) Niti Goel et al.   mAbs

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis

(2009) Roger Palframan et al.   JOURNAL OF IMMUNOLOGICAL METHODS

The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis

(2009) Antonella Di Cesare et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

(2008) Michelle A. Lowes et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Human Antimicrobial Peptide LL-37 Suppresses Apoptosis in Keratinocytes

(2008) Clara I. Chamorro et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY